BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 29588318)

  • 1. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
    Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
    Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
    Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
    Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
    Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
    Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
    Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
    Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
    Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
    Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
    Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
    J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCR reconstitution in Jurkat reporter cells facilitates the identification of novel tumor antigens by cDNA expression cloning.
    Aarnoudse CA; Krüse M; Konopitzky R; Brouwenstijn N; Schrier PI
    Int J Cancer; 2002 May; 99(1):7-13. PubMed ID: 11948485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation.
    Leisegang M; Engels B; Schreiber K; Yew PY; Kiyotani K; Idel C; Arina A; Duraiswamy J; Weichselbaum RR; Uckert W; Nakamura Y; Schreiber H
    Clin Cancer Res; 2016 Jun; 22(11):2734-43. PubMed ID: 26667491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.
    Xue SA; Gao L; Thomas S; Hart DP; Xue JZ; Gillmore R; Voss RH; Morris E; Stauss HJ
    Haematologica; 2010 Jan; 95(1):126-34. PubMed ID: 19679884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer.
    Straetemans T; Gründer C; Heijhuurs S; Hol S; Slaper-Cortenbach I; Bönig H; Sebestyen Z; Kuball J
    Clin Cancer Res; 2015 Sep; 21(17):3957-68. PubMed ID: 25991821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.
    Orlando D; Miele E; De Angelis B; Guercio M; Boffa I; Sinibaldi M; Po A; Caruana I; Abballe L; Carai A; Caruso S; Camera A; Moseley A; Hagedoorn RS; Heemskerk MHM; Giangaspero F; Mastronuzzi A; Ferretti E; Locatelli F; Quintarelli C
    Cancer Res; 2018 Jun; 78(12):3337-3349. PubMed ID: 29615432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 17. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
    Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
    Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
    Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
    Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
    Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
    Bobisse S; Rondina M; Merlo A; Tisato V; Mandruzzato S; Amendola M; Naldini L; Willemsen RA; Debets R; Zanovello P; Rosato A
    Cancer Res; 2009 Dec; 69(24):9385-94. PubMed ID: 19996290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.